Tupasela Aaro
Centre for Medical Science and Technology Studies, Department of Public Health, University of Copenhagen , København K, Denmark .
Biopreserv Biobank. 2015 Oct;13(5):379-81. doi: 10.1089/bio.2015.0034. Epub 2015 Sep 29.
In 2012 a new biobanking law came into effect in Finland which, according to some, is one of the most comprehensive and broad national biobanking legislations in the world to date. The law covers both clinical and research collections and provides institutions with great flexibility in terms of transferring existing collections into a biobank. The law also includes provisions for individuals whose samples are stored in the biobank to request information regarding the studies in which the sample has been used. However, this provision also compels biobanks to provide an account of the significance of the research findings to their individual health. This legal provision has created tension between policy and practice in that most biobanks will struggle to interpret and apply this provision in practice. The relationship between the rights and needs to conduct research using biobank material and individual rights of access is sometimes unclear and fraught with interpretational challenges. The derivation of national interpretations of European Directives and Conventions gives rise to what I call interpretive regulatory dissonance. This is expected to be a challenge for harmonizing European and global biobanking activities in the future.
2012年,芬兰一项新的生物样本库法律生效,据一些人说,这是迄今为止世界上最全面、最广泛的国家生物样本库立法之一。该法律涵盖临床和研究样本收集,并在将现有样本库转化为生物样本库方面为机构提供了很大的灵活性。该法律还规定,样本存储在生物样本库中的个人有权要求提供有关其样本所用于研究的信息。然而,这一规定也迫使生物样本库说明研究结果对个人健康的意义。这一法律规定在政策和实践之间造成了紧张关系,因为大多数生物样本库在实际操作中难以解释和适用这一规定。使用生物样本库材料进行研究的权利和需求与个人获取信息的权利之间的关系有时并不明确,充满了解释上的挑战。对欧洲指令和公约的国家解释的推导产生了我所说的解释性监管失调。预计这将是未来协调欧洲和全球生物样本库活动的一个挑战。